// App-Quantinova.ai

P059 : Efficacy Outcomes In Cladribine Tablets-treated Patients In CLARITY Were Similar Between Patients Who Did Vs. Did Not Enter CLARITY Extension

Researchers

Presenter

  • G. Comi

Principal Investigators

  • P. Soelberg-Srensen

  • K. Rammohan

  • G. Giovannoni

  • D. Damian

  • D. Jack

  • F. Dangond

  • A. Galazka

  • D. L. Jones

  • P. Vermersch

Medical Centers

  • Universita Vita Salute San Raffaele, Milan, Italy

  • University of Copenhagen, Copenhagen E, Denmark

  • Multiple Sclerosis Center, University of Miami, Miami, FL

  • Queen Mary University of London and Blizard Institute Barts and The London School of Medicine and Dentistry London United Kingdom

  • EMD Serono, Inc, Billerica, MA

  • Merck KGaA, Darmstadt, Germany

  • Merck KGaA, Aubonne, Switzerland

  • EMD Serono, Rockland, MD

  • Universite de Lille 3, Lille, France

Locations

  • Italy

  • Denmark

  • United States

  • United Kingdom

  • Germany

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved